BVS - Bioventus: Bullish On Path To Profitability

2024-01-24 14:00:34 ET

Summary

• Shares of BVS are up more than 100% over the past year amid an ongoing financial turnaround.
• The company is benefiting from strong demand for its portfolio of minimally invasive medical treatment including therapeutic injections for osteoarthritis.
• Shares are attractively priced ahead of the Q4 earnings report where we expect management to deliver positive 2024 guidance.

Bioventus Inc. ( BVS ) has emerged as an impressive turnaround story moving forward from its troubled post-IPO period where the company faced a major setback from its failed acquisition of "CartiHeal". The stock has more than doubled over the past year with the leader in therapeutic injections for osteoarthritis capturing a new round of operating momentum in recent quarters....

For further details see: